← Back to Clinical Trials
Recruiting Phase 2 NCT07167160
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Trial Parameters
Condition Cervical Cancer
Sponsor Women's Hospital School Of Medicine Zhejiang University
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 59
Sex FEMALE
Min Age 18 Years
Max Age 70 Years
Start Date 2025-03-10
Completion 2026-12-31
All Conditions
Interventions
Camrelizumab combined with chemotherapy
Brief Summary
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Eligibility Criteria
Inclusion Criteria: 1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery; 2. Positive PD-L1 expression; 3. ECOG score ≤1 Exclusion Criteria: 1. Positive parametrium or surgical margin; 2. Incomplete radical surgery; 3. Residual target lesions; 4. Active autoimmune disease or autoimmune disease requiring systemic treatment; 5. Previous treatment with immune checkpoint inhibitors.
Related Trials
NCT05808933
Magnetic Resonance Fingerprinting for Preoperative Evaluation of Lymphovascular Space Invasion in Ea
View Trial →
NCT06276309
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
View Trial →
NCT06459687
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervi
View Trial →